2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
14
Rectal Neoplasms
10
Colonic Neoplasms
6
Stomach Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Mesothelioma, Malignant
2
Thrombocytopenia
1
Squamous Cell Carcinoma of Head and Neck
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Liver, Cancer of, Primary Resectable
1
Inoperable Esophageal Cancer Stage I-III
1
Hepatocellular Carcinoma Resectable
1
Hepatecellular Carcinoma
1
Head and Neck Squamous Cell Cancer
1
Fruquintinib
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Cancer Metastatic
1
Colon Cancer Liver Metastasis
1
Carcinoma, Hepatocellular
1
Advanced Metastatic Colorectal Cancer
1
Advanced Gastric Cancer
1
Advanced Colorectal Carcinoma
1
Advanced Colorectal Cancer
1
Interventions
Bevacizumab
19
Capecitabine
15
Oxaliplatin
11
Irinotecan
11
Cetuximab
11
Fluorouracil
10
Leucovorin
8
aflibercept
7
Panitumumab
6
trifluridine tipiracil drug combination
4
Nivolumab
4
sintilimab
3
regorafenib
3
Ipilimumab
3
Vemurafenib
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Folfox protocol
2
Drug Therapy
2
tremelimumab
1
spartalizumab
1
raltitrexed
1
pembrolizumab
1
monoclonal antibody YYB-101
1
masitinib
1
irinotecan sucrosofate
1
glucopyranosyl lipid-A
1
folfirinox
1
durvalumab
1
camrelizumab
1
balstilimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Cancer Metastatic
×
raltitrexed
×
Clear all
NCT01959061
2017-03-13
TACE
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 4
Unknown
320 enrolled